LifeMD Plunges 47% Despite Strong Revenue and Platform Expansion
LifeMD, Inc. (LFMD) fell 46.79% to lead losses in the PRISM Emerging Healthcare Index, despite reporting strong top-line Q2 growth and operational milestones. Total revenue climbed 23% year-over-year to $62.2 million, while adjusted EBITDA rose 223% to $7.1 million. The company fully repaid senior debt, launched a nationwide behavioral health offering, and acquired a virtual women’s health platform. However, a downward revision in full-year 2025 guidance, tied to temporary challenges in its Rex MD segment and slowing WorkSimpli growth, sparked investor concern and heavy selling.
Fractyl Health Sinks 47% on Heavily Dilutive Public Offering
Fractyl Health, Inc. (GUTS) dropped 46.58%, weighing on the PRISM Emerging Global Health Index, after announcing a $20 million public offering of common stock and long-dated Tranche A and Tranche B warrants. While the offering supports continued advancement of the company’s Revita and Rejuva metabolic health programs, the structure of the deal, with fixed-price warrants totaling up to $40 million, raised investor fears of dilution.
Other PRISM Mid-Day Movers:
• Myriad Genetics Inc. (MYGN) up 33.07%
• Beachbody Company Inc. (BODI) up 28.80%
• Hepion Pharmaceuticals Inc. (HEPA) up 23.44%
• Personalis, Inc. (PSNL) down 26.33%
The post PRISM Mid-Day Movers: Telehealth Turbulence and Global Health Dilution appeared first on PRISM MarketView.
